White House Delays Hemp Ban Amid Industry Pressure
· news
The White House’s Hemp Conundrum: A Tale of Influence and Interests
The Trump administration’s decision to delay a ban on intoxicating hemp products has raised eyebrows, particularly given the potential benefits for White House Chief of Staff Susie Wiles’ son-in-law, Bret Worley. As CEO of MC Nutraceuticals, a global supplier of hemp products, Worley’s company stands to gain significantly from the delay.
Worley’s connection to the White House is not coincidental; he married Wiles’ younger daughter Caroline in June, cementing his ties to the administration. MC Nutraceuticals has reportedly been lobbying industry allies to pressure lawmakers to delay the ban on hemp products containing certain amounts of THC. This push has led to a reversal by the White House on the issue.
Last fall, President Donald Trump signed a spending bill that included a ban on hemp products with specific levels of THC, aimed at preventing unregulated and potentially hazardous substances from entering the market. Now, with the White House pushing lawmakers to delay the implementation of this very ban, concerns about special interests and undue influence have come to the forefront.
The New York Times and MS NOW have revealed that MC Nutraceuticals has been lobbying industry allies to pressure lawmakers to delay the ban on hemp products, which was set to take effect on November 12. This development raises uncomfortable questions about the extent to which special interests are shaping policy in Washington.
Senator Ted Budd’s opposition to the delay is a welcome voice of reason in this debate. He argues that the White House’s new stance on the ban is “absolutely ridiculous,” given concerns about products containing delta-8 THC being marketed to children. The Food and Drug Administration has indeed expressed similar reservations, warning about the dangers of these products.
Senator Shelley Moore Capito seems willing to compromise, suggesting a month-long extension of the ban might be worth it if it means avoiding another shutdown. However, her concerns about keeping the government open do not alleviate suspicions that special interests are driving this policy decision.
The White House’s handling of this issue has created an unnecessary controversy, one that threatens to undermine public trust in government. As the spending measure is set for a vote this week, lawmakers must prioritize transparency and accountability above all else. The American people deserve to know that their elected representatives are acting in their best interests, not those of powerful special interest groups.
The push to delay the hemp product ban raises serious questions about the influence of money and power on policy decisions. As the debate rages on, one thing is clear: the public’s right to know must be upheld, and the government’s commitment to transparency and accountability must be unwavering.
Reader Views
- EKEditor K. Wells · editor
The hemp industry's influence on White House policy raises more than just eyebrows - it highlights a disturbing trend of crony capitalism. The delayed ban on intoxicating hemp products may have economic benefits for companies like MC Nutraceuticals, but what about the potential health risks to consumers? Senator Budd is right to sound the alarm about delta-8 THC's marketing to children. A critical question remains unanswered: how many other industries are shaping policy through backroom deals and lobbying efforts, at the expense of public interest?
- CMColumnist M. Reid · opinion columnist
The Trump administration's sudden about-face on hemp policy reeks of crony capitalism. The delay in implementing a ban on intoxicating hemp products benefits MC Nutraceuticals' CEO Bret Worley and raises suspicions about undue influence within the White House. However, this story only scratches the surface – what's more concerning is how widespread industry lobbying has become. It's no longer just about personal connections; it's about entire companies using their resources to shape policy. Until lawmakers address these systemic issues, we can expect more of the same special interest-driven decisions.
- CSCorrespondent S. Tan · field correspondent
The White House's about-face on hemp products reeks of crony capitalism, where policy is dictated by those with deep pockets rather than sound reasoning. While Senator Budd's opposition to the delay is commendable, we must also examine how this reversal affects the legitimacy of regulatory bodies like the FDA. Will they be seen as pawns in a game where industry influence trumps public safety concerns? The administration's actions suggest a disturbing willingness to compromise on critical health standards for the sake of lucrative special interests.